HER2-targeted antibody–drug conjugate (RC48) comprising a humanized anti-HER2 IgG1 linked to the microtubule-disrupting payload MMAE; internalized upon HER2 binding and can mediate ADCC.
HER2-targeted IgG1 antibody–drug conjugate (RC48) that binds HER2 on tumor cells, is internalized, and via a cleavable linker releases the microtubule inhibitor MMAE, which disrupts tubulin polymerization to induce G2/M arrest and apoptosis; the IgG1 Fc can also mediate ADCC.
YES
DIRECT
ADC binds HER2, is internalized, and releases MMAE to disrupt microtubules causing G2/M arrest and apoptosis; Fc can also trigger ADCC against HER2+ cells.
Anti-HER2 monoclonal antibody that blocks HER2 signaling and mediates antibody-dependent cellular cytotoxicity (ADCC).
Humanized anti-HER2 monoclonal antibody that binds HER2 (ErbB2) to inhibit HER2 signaling and dimerization, suppressing proliferation of HER2-overexpressing tumor cells, and engages Fc receptors to trigger antibody-dependent cellular cytotoxicity (ADCC).
NO
INDIRECT
Trastuzumab binds HER2 on tumor cells and its Fc engages CD16A on NK cells to trigger ADCC, killing HER2+ tumor cells, not the CD16A-expressing effector cells.
HER2-targeted antibody–drug conjugate composed of trastuzumab linked to the microtubule inhibitor DM1, delivering cytotoxic payload to HER2-overexpressing tumor cells.
HER2-targeted trastuzumab linked to the microtubule inhibitor DM1. Binds HER2 to inhibit signaling and mediate ADCC, is internalized into HER2-overexpressing tumor cells, then releases DM1 to disrupt microtubules, causing mitotic arrest and apoptosis.
YES
DIRECT
The ADC binds HER2, is internalized, and releases the DM1 payload that disrupts microtubules, causing mitotic arrest and apoptosis; Fc-mediated ADCC can also contribute.
HER2-targeted antibody–drug conjugate composed of trastuzumab linked to the microtubule inhibitor DM1, delivering cytotoxic payload to HER2-overexpressing tumor cells.
HER2-targeted trastuzumab linked to the microtubule inhibitor DM1. Binds HER2 to inhibit signaling and mediate ADCC, is internalized into HER2-overexpressing tumor cells, then releases DM1 to disrupt microtubules, causing mitotic arrest and apoptosis.
NO
INDIRECT
T-DM1 targets HER2, is internalized, and releases DM1 that binds beta-tubulin to disrupt microtubules, causing mitotic arrest and apoptosis; beta-tubulin expression alone does not determine killing.
Chimeric anti-CD20 monoclonal antibody administered intravenously that depletes CD20+ B cells, reducing anti-PLA2R autoantibodies and immune complex formation.
Chimeric anti-CD20 monoclonal antibody that binds CD20 on pre-B and mature B cells and depletes them via complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity, and apoptosis, reducing anti-PLA2R autoantibodies and immune complex formation.
YES
DIRECT
Rituximab binds CD20 on B cells and eliminates them via complement-dependent cytotoxicity and Fc-mediated ADCC; it can also induce apoptosis.